文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

未知合并用药、非处方药与超说明书用药在HIV感染者中仍是问题吗?法国23中心横断面调查结果

Are unknown co-medications, over-the-counter and off-label drug use still problems among people living with HIV? Results from a transversal survey in 23 centres in France.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

2019年12月10日至16日在法国23家医院对496例连续就诊的成人HIV感染者进行横断面调查,标准化问卷由医生填写以评估全部用药。392例(79%)存在合并用药,32%(159例)发现既往未知的合并用药或其他活性物质,11%(53例)发现潜在药物相互作用,其中47%(25/53)导致治疗方案调整。

要点

  • 79%(392/496)HIV感染者存在合并用药,17%(85/496)为多重用药(≥5种药物)。
  • 32%(159/496)发现既往未知的合并用药或其他活性物质,非处方药使用占23%(113/496)。
  • 11%(53/496)存在潜在药物相互作用,其中47%(25/53)导致治疗调整。

核心结论

  • 导致治疗调整的潜在药物相互作用在HIV感染者中仍然显著,且与年龄无关。
  • 作者认为需要投入更多时间识别所有HIV感染者的合并用药和非处方药治疗。

研究设计与样本

  • 2019年12月10日至16日在法国23家医院开展为期1周的国家级多中心横断面研究。
  • 纳入连续就诊的成人HIV感染者,由医生填写标准化问卷评估全部用药及其他活性化学物质。
  • 共纳入496例参与者,来自23个中心。

主要发现

  • 中位年龄50.6岁;抗逆转录病毒治疗方案含整合酶抑制剂者占61%(n=302)、含非核苷类逆转录酶抑制剂者占34%(n=169)、含蛋白酶抑制剂者占14%(n=70)。
  • 合并用药涉及392例(79%)HIV感染者,其中85例(17%)为多重用药(≥5种药物)。
  • 32%(n=159)的参与者发现既往未知的合并用药或其他活性物质。
  • 皮质类固醇使用占9%(n=46),质子泵抑制剂占10%(n=50);这些合并用药不因年龄范围而异。
  • 非法药物使用自我报告占11%(n=54),非处方药使用占23%(n=113);发现潜在药物相互作用者占11%(n=53),其中47%(25/53)导致治疗调整。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Polypharmacy can lead to drug-drug interactions (DDIs), especially with ART. The burden of co-medications, including over-the-counter (OTC) drugs and self-medications, could be underestimated. We aimed to investigate the proportion of people living with HIV (PLHIV) with declared and undeclared co-medications, as well as their potential burden. METHODS: We conducted a national, multicentre, 1 week cross-sectional study between 10 December and 16 December 2019 in 23 French hospitals amongst consecutive adult PLHIV presenting for a routine outpatient visit. A standardized questionnaire filled in by the physicians assessed all medications and other active chemical substances taken by the PLHIV. RESULTS: Overall we enrolled 496 participants from 23 centres. Median age was 50.6 years; ART regimens included an integrase inhibitor in 61% (n = 302), an NNRTI in 34% (n = 169) and a PI in 14% (n = 70) of the cases. Co-medications involved 392 (79%) PLHIV, among which 85 (17%) received polypharmacy (≥5 medications). Previously unknown co-medications or other active substances were found for 32% (n = 159) of the participants. Corticosteroids (9%, n = 46) and proton pump inhibitors (10%, n = 50) were frequently administered. These co-medications did not differ according to age range. Illegal drug use was declared by 11% (n = 54) and OTC drugs by 23% (n = 113) of PLHIV. Potential DDIs were discovered for 11% (n = 53), leading to treatment modifications in 47% (25/53) of cases. CONCLUSIONS: Potential DDIs that lead to therapeutic modifications remain significant whatever the age of PLHIV. More devoted time to identify co-medications and OTC treatment is needed in all PLHIV.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tetart M, Passecountrin P, Lesourd A, et al. Are unknown co-medications, over-the-counter and off-label drug use still problems among people living with HIV? Results from a transversal survey in 23 centres in France. J Antimicrob Chemother. 2023. PMID: 37757452. doi:10.1093/jac/dkad292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。